LONDON BROKER RATINGS: Next gets price target bumps after results
28th Mar 2025 09:22
(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and on Thursday: Read More
(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and on Thursday: Read More
(Alliance News) - London stocks are called to open higher on Friday, as gold reaches new record highs and investors begin to digest an upwardly revised UK economic growth reading. Read More
(Alliance News) - AstraZeneca PLC on Tuesday reported positive new study results for its lung cancer drug Tagrisso, strengthening its position as a "backbone" treatment for patients with EGFR-mutated non-small cell lung cancer, also referred to as NSCLC. Read More
(Alliance News) - Angle PLC on Friday said the results of an Eisai Co Ltd pilot study supported the capability of the Parsortix system for real-time assessment of breast cancer patient HER2 status. Read More
(Alliance News) - AstraZeneca PLC on Friday said it will establish a new global strategic research & development centre in Beijing. Read More
Hutchmed China Ltd - Hong Kong-based biopharmaceutical firm - Results from the Savannah phase 2 trial showed savolitinib plus Tagrisso achieved a clinically meaningful and durable objective response rate in patients with epidermal growth factor receptor mutated non-small cell lung cancer with high levels of MET overexpression and/or amplification, whose disease progressed on treatment with first line Tagrisso. MET refers to abnormal production of a receptor tyrosine kinase, beyond its normal levels, and is associated with tumour growth and progression. Hutchmed will present new and updated data from several studies in Paris at the European Lung Cancer Congress, which will take place between next week Wednesday and March 29. Tagrisso is a drug made by AstraZeneca PLC. Read More
(Alliance News) - AstraZeneca PLC on Monday announced an acquisition, a license agreement, regulatory approval in Europe for cancer drug Imfinzi, and a further positive product update in a busy start to the week. Read More
(Alliance News) - Stocks in London are called to open flat on Monday, as investors digest plans by Chinese officials to boost consumption there, before focus later this week turns to central bank decisions. Read More
(Alliance News) - Stock prices in London were lower midday on Friday, as investors remain nervous despite the latest pause on certain US tariffs. Read More
(Alliance News) - AstraZeneca PLC on Friday said its Imfinzi treatment has demonstrated statistically significant results in a trial testing survival rates in stomach cancers. Read More
(Alliance News) - AstraZeneca PLC on Monday said its lung cancer drug Imfinzi has been recommended for approval in the EU. Read More
(Alliance News) - Stocks were called higher on Monday morning as investors digest news of greater-than-expected acceleration in China's manufacturing sector, while Japan's saw a softer deterioration than forecast. Read More
(Alliance News) - An asthma drug has shown positive results when used to treat nasal polyps, researchers have said. Read More
(Alliance News) - AstraZeneca PLC on Friday said its breast cancer therapy, Enhertu, which is being developed jointly with Tokyo-based pharmaceutical company Daiichi Sankyo Co Ltd, has been recommended for approval in the EU. Read More
(Alliance News) - AstraZeneca PLC on Wednesday said its drug camizestrant significantly delayed disease progression in a phase III trial for advanced hormone receptor-positive breast cancer, supporting its potential as a new treatment option. Read More
(Alliance News) - The FTSE 100 ended lower on Thursday, not helped by a weak start on Wall Street, hurt by a handful of its heavyweight names going ex-dividend. Read More
(Alliance News) - European blue-chips traded mixed on Thursday afternoon, with measures in Paris and Frankfurt rising, but that same positivity eluding the FTSE 100 in London. Read More
(Alliance News) - European stocks opened mixed on Thursday, with the FTSE 100 underperforming, as Russia-Ukraine uncertainty, tariff worries and the possibility of higher for longer interest rates cloud over stocks. Read More
(Alliance News) - The FTSE 100 traded lower around midday, as gains in sterling kept a lid on some dollar earners offsetting strong gains in miners. Read More